Pheton Holdings Ltd Class A Ordinary Shares (PTHL) Research

Pheton Holdings Ltd is a specialized healthcare enterprise focused on the development and commercialization of software and devices integral to brachytherapy treatments. At the core of its offerings is a proprietary treatment planning system, a sophisticated form of radiation therapy. This system facilitates the internal placement of radioactive sources within cancer patients, a process designed to eradicate malignant cells and reduce tumor size. Specifically named FTTPS, this advanced planning tool is engineered for the treatment of diverse malignant tumors. It meticulously determines the precise target volume, calculates the optimal prescription dose, establishes critical dose limitations to safeguard at-risk organs, and ultimately generates a comprehensive dose distribution plan for brachytherapy in oncology patients. Established in 1998, the company maintains its headquarters in Beijing, China. Pheton Holdings Ltd operates as a subsidiary under the ownership of ZJW (BVI) LTD.

Market snapshot

Symbol
PTHL
Price
$0.28
Day change
-5.73%
Market cap
$2.9M
P/E ratio
-1.95x
52-week range
0.2815-32
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Biomerica, Inc. (BMRA)
  • DIH Holding US, Inc. (DHAI)
  • Inspira Technologies Oxy B.H.N. Ltd. (IINN)
  • Lifeward Ltd. (LFWD)
  • Neuphoria Therapeutics Inc. (NEUP)
  • PAVmed Inc. (PAVM)
  • TransCode Therapeutics, Inc. (RNAZ)
  • Sintx Technologies, Inc. (SINT)

Open Pheton Holdings Ltd Class A Ordinary Shares (PTHL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.